Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
MDM2/MDMX Protein Market: Competitive Landscape, Pipeline, and Market Analysis 2023
MDM2/MDMX Protein Market: Competitive Landscape, Pipeline, and Market Analysis 2023
MDM2/MDMX Proteins are homologous proteins that act as the primary negative regulators of p53 in humans. p53 is a critical tumor suppressor that is activated by various cellular stresses. p53, upon activation, acts to prevent and repair damages that may lead to tumor development. p53 must be highly regulated as its activation may lead to cellular effects such as cellular arrest and cell death. MDM2 (murine double minute 2) binds and inhibits p53, while MDMX (murine double minute X) has its own roles with p53 but also acts to stabilize MDM2. The duo is thought to be associated with the physiology of many types of cancers, such as Acute Myelogenous Leukemia (AML), Lymphomas, Sarcoma, and others. It has been seen that MDM2 is either amplified or overexpressed in various types of cancers signaling cellular overactivity that may lead to a tumor. Hence, these could act as a biomarker for certain types of cancers as it is believed to be a prognostic biomarker of Brain early-stage low-grade glioma (LLG) cancer. Research is being conducted globally to discover new and novel MDMX/MDM2 Protein molecules that function to regulate the levels of p53 protein to be used as anticancer agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the American Society of Clinical Oncology 2023 report, AML is the 2nd most common type of leukemia diagnosed in adults and children and accounts for 31% of adult leukemia cases. In 2023, it is estimated that 20,380 people in the USA will be diagnosed with AML.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Companies have various products in their pipelines, with 53 products in various stages of clinical trials. 4 products in Phase 3, 10 products in Phase 2, and 7 products are in Phase 1 of the clinical trials.
Drugs in Pipeline
Clinical Activity and Developments of MDM2/MDMX Protein
As of June 2023, companies have approximately 53 products for 537 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
navtemadlin (KRT-232) |
22 |
|
idasanutlin (RO5503781) |
19 |
|
siremadlin (HDM201) |
15 |
|
eprenetapopt (APR-246) |
13 |
|
milademetan (RAIN-32) |
11 |
MDM2/MDM2 Protein complex is said to play a major role as a modulator and negative regulator of p53 protein. It plays a dual function depending upon the environmental condition. In normal conditions, the duo suppresses p53 while in conditions of stress, they themselves are needed to be inhibited for p53 to respond to stress. Globally the prevalence rates of many types of cancers have been increasing for many years, and new therapies are being discovered globally. These are in the clinical trials for various diseases like Sarcomas, Lymphomas, AML, Acute kidney injury, and others. According to the American Cancer Society estimate, about 13,400 new soft tissue sarcomas will be diagnosed in 2023 in the USA. According to a research study, in the UK, every day, 15 people were diagnosed with Sarcoma in 2019, with the count reaching 5300 people per year. Therefore, there is a vast opportunity for the MDM2/MDMX Protein market which is expanding as the new research is being conducted globally.
The global prevalence of Chronic Myeloid Leukemia (CML), according to a study in 2022, was in the range of 0.7 to 1.5 per 100,000 people. According to the American Cancer Society, in 2023, it is estimated that about 15% of all new cases of leukemia are Chronic Myeloid Leukemia (CML), and about 1 in every 526 people, which is 8,930 people, will get a CML in his/her lifetime in the USA. The incidence was about 1.1 per 100,000 people in Europe, with 4.0 per 100,000 people aged 75 years and above, according to a research article in 2022. Therefore, there is an opportunity in the MDM2/MDMX Protein market for the players to launch new products across the globe.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
No MDM2/MDMX Inhibitors have been approved for the treatment of any disorder as of now by any regulatory authority globally.
These are being used in various indications like Peripheral Neuropathic Pain, Peripheral pain associated with osteoarthritis of the knee and Diabetic Peripheral Neuropathy, and others.
Kartos Therapeutics, Inc (USA), Novartis (Switzerland), Aprea Therapeutics Inc (Sweden), Rain Oncology (USA) and Ascentage Pharma (China) are some of the major market players for MDM2/MDMX Protein.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to Diabetes Mellitus and nerve injuries and associated pain are the key opportunities for MDM2/MDMX Protein in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.